Zilongjin for NSCLC: A Systematic Review

OBJECTIVE: To evaluate the clinical efficacy and safety of Zilongjin for NSCLC. METHODS: All randomized controlled trials of Zilongjin for NSCLC were searched from database( sinoMed,VIP,Wangfang,CNKI,pubmed,The Cochrane library) and other oncology journals. According to the inclusive and exclusive criteria,the literature was selected for extracting the data. The quality evaluation and Meta-analyses were conducted by using Revman 5. 1 sofeware. RESULTS: Six RCTs involving 346 patients were included. The quality of the trials was generally low. The results of Meta-analyses showed that the treatment group of Zilongjin combined with chemotherapy compared with the control group could increase tumor efficacy [RR = 2. 51,95% CI( 1. 22,5. 13),P = 0. 01],improve the quality of life[RR = 12. 72,95% CI( 4. 70,34. 43),P < 0. 01] and [RR = 2. 67,95% CI( 1. 11,6. 43),P = 0. 03],improve TCM syndromes[RR = 14. 56,95% CI( 5. 50,38. 55),P < 0. 01],increase NK cell activity[WMD =9. 78,95% CI( 6. 86,12. 70),P < 0. 01]and the level of IL-2[WMD = 3. 75,95% CI( 0. 55,6. 95),P = 0. 02]. Zilongjin combined with chemotherapy could relieve chemotherapy-induced nausea and vomiting,diarrhea,skin rashes and other adverse reactions,and there were no obvious side effects. CONCLUSION: Zilongjin combined with chemotherapy for NSCLC had synergy and attenuation effect. As the quality of included studies were still low,there was necessary to conduct high-quality clinical trials to confirm the efficacy and safety of treatment of Zilongjin for lung cancer. Besides,TCM showed good effect in maintenance treatment of tumors and also indicated the direction of Zilongjin clinical studies.